In addition, during the introduction of the biosimilar rhGH, a report from the French SAGhE (Safety and Appropriateness of Growth Hormone Treatments in Europe) study suggested an increased risk of mortality due to bone tumors and cerebrovascular diseases in patients with GHD, ISS, or SGA treated with rhGH during childhood [31]. This evidence concerns the gene GH1 and cerebrovascular disorder.